← Back to Search

Iron Supplement

Iron Infusion Arm for Cancer-related Anemia

Q: Has the Iron Infusion Arm received official approval from the FDA?

<p>Based on our evaluations, the Iron Infusion Arm has been rated a level 3 in terms of safety by Power's team. This rating is attributed to the trial being classified as Phase 3, indicating existing efficacy data and robust safety records.</p>

Q: Are there any available openings for patients to participate in this medical study?

<p>As per clinicaltrials.gov, this particular study is not in the current phase of participant recruitment. The trial was initiated on February 29th, 2024 and last updated on February 5th, 2024. Despite its closure for enrollment, it's worth noting that there are approximately 230 alternative studies actively seeking participants at present.</p>

Phase 3

Waitlist Available

Led By Maryam Al-Hayki

Research Sponsored by University of Saskatchewan

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients on any active cancer treatment or with history of previous chemotherapy, surgery, radiation, PARP, biologics, and hormonal treatment

Perioperative patients having upfront surgery or at interval or secondary debulking surgery

Timeline

Screening 3 weeks

Treatment Varies

Follow Up hgb will be checked just prior to treatment and then biweekly until week 8 or whenever hgb rises at least by 20 g/l through the treatment period, upto 3 years.

Awards & highlights

Study Summary

This trial aims to investigate the use of intravenous (IV) iron infusion in managing anemia in patients with ovarian cancer. Anemia is a common issue in cancer patients and can impact their treatment outcomes

Who is the study for?

This trial is for ovarian cancer patients who are experiencing anemia, either as a new symptom or during their cancer treatment. It's important that participants have not had any iron treatments recently and do not have other medical conditions that could affect the study results.Check my eligibility

What is being tested?

The trial is testing whether giving iron directly into the bloodstream can help with anemia in people with ovarian cancer. The goal is to see if this improves how long they live, their energy levels, and overall well-being.See study design

What are the potential side effects?

Possible side effects of IV iron infusion include allergic reactions, infections at the injection site, changes in blood pressure, headaches, dizziness, nausea or vomiting.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have had cancer treatments like chemotherapy, surgery, or hormone therapy.

Select...

I am scheduled for or have had surgery to remove a tumor.

Select...

I am a woman aged 18 or older.

Select...

I am fit for cancer treatment and expected to live more than 6 months.

Select...

I have had 2 or fewer chemotherapy treatments.

Select...

My ovarian cancer is confirmed and is stage IC-IV.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ hgb will be checked just prior to treatment and then biweekly until week 8 or whenever hgb rises at least by 20 g/l through the treatment period, upto 3 years.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~hgb will be checked just prior to treatment and then biweekly until week 8 or whenever hgb rises at least by 20 g/l through the treatment period, upto 3 years.

This trial's timeline: 3 weeks for screening, Varies for treatment, and hgb will be checked just prior to treatment and then biweekly until week 8 or whenever hgb rises at least by 20 g/l through the treatment period, upto 3 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in QOL (quality of Life)

Delay In Chemotherapy

Efficiency of IV iron

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Iron Infusion ArmExperimental Treatment1 Intervention

Group A: Treatment study group All patients will be treated with iron infusion for Hgb lower than 100 g/L and/or TSAT < 20%.

Group II: No Iron InfusionActive Control1 Intervention

Group B: No iron Infusion

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

IV iron

2015

Completed Phase 3

~80

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of SaskatchewanLead Sponsor

251 Previous Clinical Trials

154,210 Total Patients Enrolled

Maryam Al-HaykiPrincipal InvestigatorUniversity of Saskatchewan

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Iron Infusion Arm received official approval from the FDA?

"Based on our evaluations, the Iron Infusion Arm has been rated a level 3 in terms of safety by Power's team. This rating is attributed to the trial being classified as Phase 3, indicating existing efficacy data and robust safety records."

Answered by AI

Are there any available openings for patients to participate in this medical study?

"As per clinicaltrials.gov, this particular study is not in the current phase of participant recruitment. The trial was initiated on February 29th, 2024 and last updated on February 5th, 2024. Despite its closure for enrollment, it's worth noting that there are approximately 230 alternative studies actively seeking participants at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer

Maryam Al-Hayki 2024. "Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06248749.